九典制药(300705) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 449,062,914.36, representing a 61.47% increase compared to CNY 278,106,139.44 in the same period last year[3]. - Net profit attributable to shareholders was CNY 55,965,884.89, up 20.49% from CNY 46,447,471.21 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 54,475,155.84, reflecting a 47.21% increase from CNY 37,005,821.13 in the previous year[3]. - Basic and diluted earnings per share increased to CNY 0.24, a 20.00% rise from CNY 0.20 in the previous year[3]. - Total operating revenue for the first quarter was CNY 449,062,914.36, an increase from CNY 278,106,139.44 in the previous year, representing a growth of 61.4%[24]. - Net profit for the first quarter reached CNY 55,965,884.89, compared to CNY 46,447,471.21 in the same period last year, reflecting a year-over-year increase of 20.5%[27]. Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of CNY -1,848,282.70, a decline of 114.22% compared to a net inflow of CNY 13,000,922.98 in the same period last year[3]. - The cash inflow from operating activities totaled approximately ¥501.68 million, a significant increase from ¥298.41 million in the previous period, representing a growth of about 68%[31]. - The cash outflow from operating activities amounted to approximately ¥503.52 million, compared to ¥285.41 million in the prior period, indicating an increase of around 76%[34]. - The net cash flow from operating activities was negative at approximately -¥1.85 million, a decline from a positive ¥13.00 million in the previous period[34]. - Cash inflow from investment activities was approximately ¥160.85 million, while cash outflow was about ¥76.33 million, resulting in a net cash flow from investment activities of approximately ¥84.53 million[34]. - The net increase in cash and cash equivalents was approximately ¥78.65 million, compared to ¥6.95 million in the previous period, reflecting a substantial improvement[34]. - The ending balance of cash and cash equivalents stood at approximately ¥455.05 million, up from ¥138.47 million at the end of the previous period[37]. - The company reported a significant increase in cash received from sales of goods and services, totaling approximately ¥487.45 million, compared to ¥278.44 million previously, marking a growth of about 75%[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,769,440,435.14, a 1.39% increase from CNY 1,745,236,782.31 at the end of the previous year[3]. - The total liabilities decreased to CNY 613,765,871.88 from CNY 645,899,203.77, indicating a reduction of approximately 5%[23]. - The total equity attributable to shareholders increased to CNY 1,155,674,563.26 from CNY 1,099,337,578.54, marking a growth of 5.1%[23]. - The total non-current assets decreased slightly to ¥721,047,512.86 from ¥724,964,584.98, showing a decline of about 0.5%[17]. Expenses - The company's R&D expenses rose to CNY 34,289,853.06, an increase of 43.77% compared to CNY 23,849,997.16 in the previous year, indicating a focus on new product development[6]. - The company reported a significant increase in sales expenses, which reached CNY 237,781,400.74, up 79.98% from CNY 132,112,583.11, reflecting enhanced market expansion efforts[6]. - The company's total operating costs were CNY 386,227,834.47, compared to CNY 233,213,680.72 in the previous year, reflecting a rise of 65.7%[24]. - The company experienced a 297.01% increase in financial expenses, amounting to CNY 3,675,983.98, mainly due to increased convertible bond interest[6]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,005, with the largest shareholder, Zhu Zhihong, holding 35.75% of shares, amounting to 83,910,000 shares[10]. - The largest shareholder, Zhu Zhihong, holds 20,977,500 unrestricted shares[10]. - The company has not disclosed any related party relationships among the top ten shareholders[13]. - The company has not reported any changes in restricted shares during the period[14]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[26].